An expert explains what biliary tract cancers are and the current landscape of treatment as well as future advancements. In the treatment of newly diagnosed biliary tract cancer, the current standard ...

The biliary tract cancer market is experiencing steady growth driven by rising global incidence and improved diagnostic ...

ctDNA is a valuable prognostic biomarker for relapse in early-stage BTC, outperforming carbohydrate antigen 19-9 levels. ctDNA monitoring can detect molecular recurrence earlier than standard ...

Credit: Jazz Pharmaceuticals Zanidatamab is a bispecific antibody that binds to 2 non-overlapping extracellular epitopes of the HER2 receptor. Findings showed the ORR was 52% (95% CI, 39-65), of which ...

Zanidatamab-hrii received FDA accelerated approval for HER2-positive biliary tract cancer, showing a 52% objective response rate in the HERIZON-BTC-01 trial. Biliary tract cancers represent 3% of ...

The international group of experts, including Professor John Bridgewater (UCL Cancer Institute), is calling for rapid ...

At its April 2025 meeting, the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) gave a conditional marketing authorization for Ziihera (zanidatamab, Jazz ...

Biliary tract cancers, including cholangiocarcinoma and gallbladder carcinoma, represent a heterogeneous group of malignancies with rising global incidence and persistent dismal prognoses. Research in ...

Please provide your email address to receive an email when new articles are posted on . The FDA granted accelerated approval to zanidatamab-hrii for treatment of adults with previously treated ...

Compass Therapeutics' tovecimig shows promise in biliary tract cancer with a 17.1% response rate, but further survival data is crucial for potential approval. CMPX's cash runway extends into early ...

Academic-center care was independently associated with higher complete oncologic resection rates and improved overall survival versus nonacademic facilities after adjustment for age, comorbidity, and ...

The FDA on Wednesday granted accelerated approval to zanidatamab (Ziihera), a bispecific antibody, for pretreated HER2-positive biliary tract cancer. Approval stipulates use in unresectable or ...